Fig 1.
Preferences selection flow diagram.
Table 1.
Characteristics of the included clinical studies†.
Fig 2.
Absolute risk for HBV reactivation in HBsAg-positive lung cancer patients without(2A) or with (2B) antiviral prophylaxis.
Fig 3.
Risk ratio of HBV reactivation comparing antiviral prophylaxis with non-prophylaxis in HBsAg-positive lung cancer patients.
Fig 4.
Risk ratio of hepatitis and chemotherapy disruption comparing antiviral prophylaxis with non-prophylaxis in HBsAg-positive lung cancer patients.
Table 2.
Hepatitis B virus screening and antiviral prophylaxis strategy prior to immunosuppressive therapy by different major guidelines.